Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.
Chinese firm RareStone licenses Rhythm’s Imcivree in greater China and will help enroll label-expansion studies for the drug. Omeros sells ophthalmic surgery drug Omidria and its commercial team to Rayner Surgical Group.
CEO David Meeker spoke with Scrip about how the company is targeting its drug, Imcivree, across potentially dozens of rare genetic diseases of obesity.